Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Medigen shares COVID vaccine tech with WHO in world-first deal


The Taiwanese biotech firm is the first commercial entity to share IP and know-how via a WHO pool set up in 2020

Taiwanese biotech firm Medigen yesterday, August 29, became the first commercial entity to share COVID vaccine technology with the World Health Organization.

Medigen’s vaccine unit was among three licensors to share tech via the WHO’s COVID-19 Technology Access Pool (C-TAP) in new deals, alongside research institutes in Spain and Chile.

The deals involve the licensing of patents as well as the sharing of know-how, materials, and clinical data.

More than three million doses of Medigen's vaccine have been administered across seven countries.

The Spanish National Research Council (CSIC) agreed to share access to a COVID vaccine prototype while the University of Chile will share tech for a COVID antibody test.

“COVID-19 is here to stay, and the world will continue to need tools to prevent it, test for it and treat it,” said Tedros Adhanom Ghebreyesus, WHO director-general.

“I am grateful to the leadership shown by those licence holders who have contributed technology,” he added.

Charles Chen, CEO of Medigen Vaccine Biologics, said solidarity and cooperation were the foundations of an effective pandemic response.

“This is not just about COVID-19; it is about setting a precedent for future global health challenges.

“We hope to inspire other organisations to follow suit,” Chen said.

Previously, only two public health institutes – the CSIC, which signed a separate deal with C-TAP in 2021, and the US National Institute of Health – had agreed to license tech through the WHO pool since it was set up in 2020.

Access to medicine campaigners welcomed the news as a “significant step” and urged major COVID vaccine makers to share their intellectual property.

Julia Kosgei, policy co-lead for campaign group the People’s Vaccine Alliance, said: “By sharing technology with C-TAP, these organisations are placing the needs of humanity over the narrow perception of profit and self-interest that has so far plagued the pharmaceutical industry.”

“It is shameful that, despite receiving unprecedented public funding and advance purchases, not even one of the major pharmaceutical companies has shared vaccine technology with C-TAP,” Kosgei added.

Negotiations for a pandemic prevention treaty, including potential reforms to the global intellectual property system, are currently ongoing at the WHO.

more from across site and ros bottom lb

More from across our site

Cyril Amarchand Mangaldas has hired former Anand & Anand partner Swati Sharma and hopes to compete with specialist IP firms
Rapporteur-Judge András Kupecz ruled that education and training weren’t legitimate reasons for a member of the public to access documents
Searches for comparison prior art will be a little easier, but practitioners will have to put more thought into claim construction and design patent titles
The Helsinki local division rejected AIM Sport’s request for a preliminary injunction in a dispute with rival Supponor
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
The FTC’s plans to scrutinise improperly listed Orange Book patents could make these listings more important in litigation, but firms should be looking at this anyway
Counsel at Debevoise & Plimpton explain how they helped food delivery business Grubhub avoid a preliminary injunction at the Court of Appeals for the Seventh Circuit
European lawyers tell Managing IP how the legal market is reacting to the first few months of the UPC and why cases are set to take off
The ban could be extended or cancelled, depending on whether Judge Pauline Newman cooperates with an investigation, the Judicial Council of the Federal Circuit stated
Sources say some China-based lawyers are prepared to take large pay cuts to join stable practices, but most firms are sceptical about new hires